Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease

Korean Journal of Internal Medicine

Volumn 24, Issue 1, 2009, Pages 73-75

  Kim, Dong Min ^a   Kim, Hyun Lee ^a   Chung, Choon Hae ^a   Park, Chi Young ^a  

^a Chosun University   (South Korea)

Author keywords

Hemodialysis; Irinotecan; Small cell lung cancer

Indexed keywords

IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE;

ADULT; ANOREXIA; ARTICLE; CASE REPORT; FATIGUE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; FOLLOW UP; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; RENAL DIALYSIS; SMALL CELL LUNG CARCINOMA;

EID: 64249154711     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.1.73     Document Type: Article

References (13)

1. Rosen LS. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park) 1998;12(8 Suppl 6):103-109.
2. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999;35:371-379.
3. Negoro S, Fukuoka M, Niitani H. Phase II study of CPT-11, a new camptothcin derivative, in small cell lung cancer. Proc Am Soc Clin Oncol 1991;10:24.
4. Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4:2747-2754. (Pubitemid 28523501)
5. Mencoboni M, Olivieri R, Vannozzi MO, Schettini G, Viazzi F, Ghio R. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Chemotherapy 2006;52:147-150. (Pubitemid 43760312)
6. Jeyabalan N, Hirte HW, Moens F. Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. Int J Gynecol Cancer 2000;10:463-468. (Pubitemid 32066629)
7. Kiani A, Kohne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003;51:266-270. (Pubitemid 36469958)
8. Ono S, Miyazaki T, Nishikawa K, Watanabe K, Hisanaga S. Etoposide and cisplatin combination chemotherapy in a patient with small cell lung carcinoma under artificial hemodialysis. Gan To Kagaku Ryoho 1992;19:115-118.
9. Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004;15:51-54. (Pubitemid 38139603)
10. Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003;88:25-30. (Pubitemid 36241213)
11. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-221.
12. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 2002;25:60-63. (Pubitemid 34224995)
13. Bae SB, Lee NS, Kim HJ, et al. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer. Cancer Res Treat 2006;38:72-77.